{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:25:02Z","timestamp":1792790702959,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Galala University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetol Metab Syndr"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Automated insulin delivery showed better results than standard insulin therapy, such as MDI. Therefore, we aimed to discuss the efficacy of Control IQ hybrid closed loop (HCL) during the daytime and nighttime for the type 1 diabetic population without restriction in age group or disease severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched PubMed, Scopus, Cochrane Library, Web of Science, and related article citations. We analyzed the time in range (TIR), time below range (TBR), time above range (TAR), HBA1c, and serious adverse events (AEs) to ensure safety and efficacy. We used a random effects model when heterogeneity was present; otherwise, we used a fixed effects model. Data was presented as mean difference and 95% confidence intervals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We selected seven randomized controlled trials (RCTs) out of 1339 articles for the analysis. After analysis of pooled studies data, Control IQ showed improvement in TIR 70\u2013180\u00a0mg\/dl 24\u00a0h data (MD 11.75%, CI 95% (9.54 to 13.97),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.000001) with a similar effect observed in daytime and nighttime. Significant reduction in HbA1c (MD -0.38%, CI 95% (-0.55 to -0.22),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.00001) and 24-hour coefficient variation (CV) measurement (MD -1.42%, CI 95% (-2.22 to -0.61),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.0006) in the Control IQ group compared to the standard therapy group. However, daytime TBR\u2009&lt;\u200970\u00a0mg\/dl did not show significant improvement (MD -0.22%, CI 95% (-0.50 to 0.06),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12). Regarding safety, Control IQ reduction in DKA was insignificant (OR 1.48 (CI 95%: 0.23\u20139.55),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.68).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Control IQ showed better blood glucose control than standard insulin therapy, with some considerations regarding daytime glycemic control that need further assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13098-025-01906-2","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T03:00:43Z","timestamp":1754967643000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Daytime and nighttime glycemic control with control-IQ technology vs. standard therapy in type 1 diabetes: a systematic review and meta-analysis with trial sequential analysis and GRADE assessment"],"prefix":"10.1186","volume":"17","author":[{"given":"Rahma Mogahed","family":"Rateb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Salah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Kertam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youssef Adel Youssef","family":"Ashmawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nourhan Hatem","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eslam","family":"Afifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Bayoumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salma","family":"Allam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Saad","family":"Rakab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"1906_CR1","doi-asserted-by":"crossref","unstructured":"Hruby A, Hu FB. The epidemiology of obesity: a big picture. PharmacoEconomics. 2015;33(7):673\u201389.","DOI":"10.1007\/s40273-014-0243-x"},{"issue":"12","key":"1906_CR2","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1007\/s00125-021-05568-3","volume":"64","author":"RIG Holt","year":"2021","unstructured":"Holt RIG, DeVries JH, Hess-Fischl A, Hirsch IB, Kirkman MS, Klupa T, et al. The management of type 1 diabetes in adults. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetologia. 2021;64(12):2609\u201352.","journal-title":"Diabetologia"},{"issue":"1","key":"1906_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2337\/dc13-2112","volume":"37","author":"DM Nathan","year":"2014","unstructured":"Nathan DM, for the DCCT\/EDIC Research Group. The diabetes control and complications trial\/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37(1):9\u201316.","journal-title":"Diabetes Care"},{"issue":"1","key":"1906_CR4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.5114\/pedm.2023.126359","volume":"29","author":"S Seget","year":"2023","unstructured":"Seget S, Tekielak A, Rusak E, Jarosz-Chobot P. Commercial hybrid closed-loop systems available for a patient with type 1 diabetes in 2022. Pedm. 2023;29(1):30\u20136.","journal-title":"Pedm"},{"issue":"3","key":"1906_CR5","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1111\/dom.14273","volume":"23","author":"L Leelarathna","year":"2021","unstructured":"Leelarathna L, Choudhary P, Wilmot EG, Lumb A, Street T, Kar P, et al. Hybrid closed-loop therapy: where are we in 2021? Diabetes Obes Metabolism. 2021;23(3):655\u201360.","journal-title":"Diabetes Obes Metabolism"},{"issue":"12","key":"1906_CR6","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.2337\/dc23-0685","volume":"46","author":"E Renard","year":"2023","unstructured":"Renard E, Joubert M, Villard O, Dreves B, Reznik Y, Farret A, et al. Safety and efficacy of sustained automated insulin delivery compared with sensor and pump therapy in adults with type 1 diabetes at high risk for hypoglycemia: a randomized controlled trial. Diabetes Care. 2023;46(12):2180\u20137.","journal-title":"Diabetes Care"},{"issue":"5","key":"1906_CR7","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1089\/dia.2022.0558","volume":"25","author":"RW Beck","year":"2023","unstructured":"Beck RW, Kanapka LG, Breton MD, Brown SA, Wadwa RP, Buckingham BA, et al. A meta-analysis of randomized trial outcomes for the t:slim X2 insulin pump with control-IQ technology in youth and adults from age 2 to 72. Diabetes Technol Ther. 2023;25(5):329\u201342.","journal-title":"Diabetes Technol Ther"},{"issue":"4","key":"1906_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1089\/dia.2019.0011","volume":"21","author":"GP Forlenza","year":"2019","unstructured":"Forlenza GP, Ekhlaspour L, Breton M, Maahs DM, Wadwa RP, DeBoer M, et al. Successful at-home use of the tandem control-IQ artificial pancreas system in young children during a randomized controlled trial. Diabetes Technol Ther. 2019;21(4):159\u201369.","journal-title":"Diabetes Technol Ther"},{"key":"1906_CR9","doi-asserted-by":"crossref","unstructured":"Ekhlaspour L, Forlenza GP, Chernavvsky D, Maahs DM, Wadwa RP, Deboer MD et al. Closed loop control in adolescents and children during winter sports: use of the tandem control-IQ AP system. Pediatr Diabetes. 2019 [cited 2025 July 20]; Available from: https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pedi.12867","DOI":"10.1111\/pedi.12867"},{"key":"1906_CR10","doi-asserted-by":"crossref","unstructured":"Cobry EC, Kanapka LG, Cengiz E, Carria L, Ekhlaspour L, Buckingham BA et al. Health-related quality of life and treatment satisfaction in parents and children with type 1 diabetes using closed-loop control. Diabetes Technology & Therapeutics. 2021;23(6):401\u20139.","DOI":"10.1089\/dia.2020.0532"},{"key":"1906_CR11","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1906_CR12","unstructured":"Cochrane Handbook for Systematic Reviews of Interventions. (current version)| Cochrane. [cited 2025 July 5]. Available from: https:\/\/www.cochrane.org\/authors\/handbooks-and-manuals\/handbook\/current"},{"key":"1906_CR13","doi-asserted-by":"publisher","unstructured":"Rayyan\u2014a web and mobile app for systematic reviews| Systematic Reviews| Full Text. [cited 2025 July 16]. Available from: https:\/\/systematicreviewsjournal.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/s13643-016-0384-4","DOI":"10.1186\/s13643-016-0384-4"},{"key":"1906_CR14","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"7650","key":"1906_CR15","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ: Br Med J. 2008;336(7650):924.","journal-title":"BMJ: Br Med J"},{"key":"1906_CR16","unstructured":"RevMan. 2020. The Cochhrane collaboration; 2020. Available from: revman.cochrane.org."},{"key":"1906_CR17","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","volume":"14","author":"X Wan","year":"2014","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol. 2014;14:135.","journal-title":"BMC Med Res Methodol"},{"key":"1906_CR18","doi-asserted-by":"crossref","unstructured":"Lin L, Chu H. Quantifying publication bias in meta-analysis. Biometrics. 2018;74(3):785\u201394.","DOI":"10.1111\/biom.12817"},{"issue":"2","key":"1906_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.17085\/apm.21038","volume":"16","author":"H Kang","year":"2021","unstructured":"Kang H. Trial sequential analysis: novel approach for meta-analysis. Anesth Pain Med (Seoul). 2021;16(2):138\u201350.","journal-title":"Anesth Pain Med (Seoul)"},{"issue":"9","key":"1906_CR20","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa2004736","volume":"383","author":"MD Breton","year":"2020","unstructured":"Breton MD, Kanapka LG, Beck RW, Ekhlaspour L, Forlenza GP, Cengiz E, et al. A randomized trial of closed-loop control in children with type 1 diabetes. N Engl J Med. 2020;383(9):836\u201345.","journal-title":"N Engl J Med"},{"issue":"8","key":"1906_CR21","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.2337\/dc20-0124","volume":"43","author":"SA Brown","year":"2020","unstructured":"Brown SA, Beck RW, Raghinaru D, Buckingham BA, Laffel LM, Wadwa RP, et al. Glycemic outcomes of use of CLC versus PLGS in type 1 diabetes: a randomized controlled trial. Diabetes Care. 2020;43(8):1822\u20138.","journal-title":"Diabetes Care"},{"issue":"18","key":"1906_CR22","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","volume":"381","author":"SA Brown","year":"2019","unstructured":"Brown SA, Kovatchev BP, Raghinaru D, Lum JW, Buckingham BA, Kudva YC, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707\u201317.","journal-title":"N Engl J Med"},{"issue":"11","key":"1906_CR23","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMoa2210834","volume":"388","author":"RP Wadwa","year":"2023","unstructured":"Wadwa RP, Reed ZW, Buckingham BA, DeBoer MD, Ekhlaspour L, Forlenza GP, et al. Trial of hybrid closed-loop control in young children with type 1 diabetes. N Engl J Med. 2023;388(11):991\u20131001.","journal-title":"N Engl J Med"},{"key":"1906_CR24","doi-asserted-by":"publisher","first-page":"102852","DOI":"10.1016\/j.eclinm.2024.102852","volume":"76","author":"T Roos","year":"2024","unstructured":"Roos T, Hermanns N, Gro\u00df C, Kulzer B, Haak T, Ehrmann D. Effect of automated insulin delivery systems on person-reported outcomes in people with diabetes: a systematic review and meta-analysis. eClinicalMedicine. 2024;76:102852.","journal-title":"eClinicalMedicine"},{"issue":"2","key":"1906_CR25","doi-asserted-by":"publisher","first-page":"e002633","DOI":"10.1136\/bmjdrc-2021-002633","volume":"10","author":"X Jiao","year":"2022","unstructured":"Jiao X, Shen Y, Chen Y, Better TIR. HbA1c, and less hypoglycemia in closed-loop insulin system in patients with type 1 diabetes: a meta-analysis. BMJ Open Diab Res Care. 2022;10(2):e002633.","journal-title":"BMJ Open Diab Res Care"},{"issue":"2","key":"1906_CR26","doi-asserted-by":"publisher","first-page":"e64","DOI":"10.1016\/S2589-7500(19)30218-3","volume":"2","author":"BP Kovatchev","year":"2020","unstructured":"Kovatchev BP, Kollar L, Anderson SM, Barnett C, Breton MD, Carr K, et al. Evening and overnight closed-loop control versus 24\/7 continuous closed-loop control for type 1 diabetes: a randomised crossover trial. Lancet Digit Health. 2020;2(2):e64\u201373.","journal-title":"Lancet Digit Health"},{"key":"1906_CR27","doi-asserted-by":"crossref","unstructured":"Feng Zqin, Guo Qyu, Wang W, Yuan Y, yu, Jin X, guang, Zhou H et al. Time in range, especially overnight time in range, is associated with sudomotor dysfunction in patients with type 1 diabetes. Diabetol Metab Syndr. 2021 [cited 2025 July 21];13(1). Available from: https:\/\/dmsjournal.biomedcentral.com\/articles\/10.1186\/s13098-021-00739-z","DOI":"10.1186\/s13098-021-00739-z"},{"key":"1906_CR28","doi-asserted-by":"crossref","unstructured":"Aiello EM, Deshpande S, \u00d6zaslan B, Wolkowicz KL, Dassau E, Pinsker JE, et al. Review of automated insulin delivery systems for individuals with type 1 diabetes: tailored solutions for subpopulations. Curr Opin Biomedical Eng. 2021;19:100312.","DOI":"10.1016\/j.cobme.2021.100312"},{"issue":"3","key":"1906_CR29","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1089\/dia.2020.0318","volume":"23","author":"M Christiansen","year":"2021","unstructured":"Christiansen M, Bartee A, Lalonde A, Jones RE, Katz M, Wolpert H, et al. Performance of an automated insulin delivery system: results of early phase feasibility studies. Diabetes Technol Ther. 2021;23(3):187\u201394.","journal-title":"Diabetes Technol Ther"},{"issue":"2","key":"1906_CR30","doi-asserted-by":"publisher","first-page":"e002039","DOI":"10.1136\/bmjdrc-2020-002039","volume":"9","author":"N Suleiman","year":"2021","unstructured":"Suleiman N, Alkasem M, Hassoun S, Abdalhakam I, Bettahi I, Mir F, et al. Insulin sensitivity variations in apparently healthy Arab male subjects: correlation with insulin and C peptide. BMJ Open Diab Res Care. 2021;9(2):e002039.","journal-title":"BMJ Open Diab Res Care"},{"key":"1906_CR31","doi-asserted-by":"crossref","unstructured":"Bellido V, Aguilera E, Cardona-Hernandez R, Diaz-Soto G, De Gonz\u00e1lez P\u00e9rez N, Pic\u00f3n-C\u00e9sar MJ, et al. Expert recommendations for using time-in-range and other continuous glucose monitoring metrics to achieve patient-centered glycemic control in people with diabetes. J Diabetes Sci Technol. 2023;17(5):1326\u201336.","DOI":"10.1177\/19322968221088601"},{"key":"1906_CR32","doi-asserted-by":"crossref","unstructured":"Garcia-Tirado J, Colmegna P, Villard O, Diaz JL, Esquivel-Zuniga R, Koravi CLK et al. Assessment of meal anticipation for improving fully automated insulin delivery in adults with type 1 diabetes. Diabetes Care. 2023;46(9):1652\u20138.","DOI":"10.2337\/dc23-0119"},{"issue":"1","key":"1906_CR33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S2213-8587(22)00319-9","volume":"11","author":"T Battelino","year":"2023","unstructured":"Battelino T, Alexander CM, Amiel SA, Arreaza-Rubin G, Beck RW, Bergenstal RM, et al. Continuous glucose monitoring and metrics for clinical trials: an international consensus statement. Lancet Diabetes Endocrinol. 2023;11(1):42\u201357.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1906_CR34","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/endrev\/bnac022","volume":"44","author":"M Phillip","year":"2023","unstructured":"Phillip M, Nimri R, Bergenstal RM, Barnard-Kelly K, Danne T, Hovorka R, et al. Consensus recommendations for the use of automated insulin delivery technologies in clinical practice. Endocr Rev. 2023;44(2):254\u201380.","journal-title":"Endocr Rev"},{"key":"1906_CR35","doi-asserted-by":"crossref","unstructured":"Pala L, Dicembrini I, Mannucci E. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials. Acta Diabetol. 2019;56(9):973\u201380.","DOI":"10.1007\/s00592-019-01326-5"},{"key":"1906_CR36","unstructured":"O\u2019Neal TB, Luther EE. Dawn phenomenon. In: StatPearls [Internet]. StatPearls Publishing; 2023 [cited 2025 July 21]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK430893\/"}],"container-title":["Diabetology &amp; Metabolic Syndrome"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13098-025-01906-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13098-025-01906-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T10:44:48Z","timestamp":1781606688000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13098-025-01906-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1906"],"URL":"https:\/\/doi.org\/10.1186\/s13098-025-01906-2","relation":{},"ISSN":["1758-5996"],"issn-type":[{"value":"1758-5996","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]},"assertion":[{"value":"21 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"325"}}